INTRODUCTION
Many clinical disorders tend not to emerge until later life. Huntington's disease, for example, usually is not diagnosed until at least the fifth decade, Parkinson's the sixth, and Alzheimer's not until still later. Several explanations might be offered for the late appearance of these disorders. First, the underlying neurodegenerative conditions may simply exhibit a late onset. Yet, the evidence suggests otherwise. Postmortem analyses of patients identified as having one of these conditions inevitably uncover extensive neuropathology even if premorbid neurological symptoms had been mild. It is, of course, possible that once the neurodegenerative process is initiated it has a precipitous time course. Yet this seems unlikely, too, since when the clinical symptoms of most such conditions do become apparent, they usually progress over a period of 10-15 years or more, suggesting an equally slow underlying process.
A second possibility is that there is great redundancy in brain and, thus, it is possible to lose 50% or more of a particular set of neurons with no need for any modification in the remaining tissue. However, evidence from the study Parkinson's disease and related animal models suggests otherwise. Indeed, these observations indicate that a host of active compensatory processes serve to delay the onset of frank neurological symptoms. Furthermore, the evidence suggests that many if not all of the compensations occur within the remaining elements of the damaged system rather than in some distal portion of the circuitry.
AN ANIMAL MODEL OF PARKINSONISM
6-Hydroxydopamine (6-OHDA) is an analogue of dopamine (DA) that can be administered directly into brain. The neurotoxin then is selectively transported into catecholaminergic neurons via high-affinity catecholamine transporters, where it oxidizes to form such cytotoxic compounds as hydrogen peroxide (H 2 O 2 ) and 6-OHDA-quinone. This can lead to the selective degeneration of the neurons (see review by Zigmond & Keefe, 1997) .
The intracerebral administration of this drug to produce large, permanent, and selective lesions of DA neurons of the nigrostriatal projection can cause severe neurological deficits, such as akinesia, decreased nutrient intake, and sensory neglect (Ungerstedt, 1971; Zigmond & Stricker, 1972 , 1973 Marshall & Teitelbaum, 1973) . However, such gross behavioral impairments occur only in animals with very large depletions of DA. Moreover, even these animals often recover from the initial deficits caused by large DA depletions so long as some minimal amount of striatal DA remains (Ungerstedt, 1971; Zigmond & Stricker, 1973) .
In short, while not replicating all of the neurological or neuropathological features of parkinsonism, 6-OHDA does cause both selective loss of DA and neurological impairments reminiscent of several key features of the disorder. Moreover, as in the case of Parkinson's disease, the gross neurological deficits do not occur until the loss of DA is extreme. What is the basis for this extended preclinical state?
